Equities

Laekna Inc

Laekna Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.59
  • Today's Change0.13 / 2.01%
  • Shares traded11.88m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-399.15m
  • Incorporated2016
  • Employees89.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hua Medicine82.91m-228.61m1.60bn177.00--13.59--19.35-0.2339-0.23390.08490.11190.05381.691.98468,423.00-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80------
Immunotech Biopharm Ltd0.00-362.36m1.74bn210.00--9.28-----0.7042-0.70420.000.36510.00----0.00-38.88-37.42-50.88-45.48--------1.03-1.970.4327-------5.25------
Dawnrays Pharmaceutical (Holdings) Ltd1.25bn352.81m1.82bn1.14k5.160.58764.011.460.23470.23470.82912.060.31562.316.371,089,958.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Cryofocus Medtech Shanghai Co Ltd44.32m-105.50m1.89bn392.00--10.81--42.62-0.4412-0.44120.18540.7308------113,056.10--------75.83---258.23--4.08--0.0597--50.83--13.13------
SinoMab Bioscience Ltd1.48m-263.11m2.02bn233.00--5.99--1,367.22-0.2584-0.25840.00150.30910.0015-------26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---8.150.604------14.45------
Acotec Scientific Holdings Ltd512.82m15.68m2.02bn638.00123.701.4430.753.940.05210.05211.704.480.31360.72133.44803,793.300.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
Cutia Therapeutics148.94m-2.13bn2.16bn298.00--1.47--14.49-6.99-6.990.48994.80------499,805.20--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
Abbisko Cayman Ltd20.63m-467.08m2.42bn258.00--1.13--117.44-0.7217-0.72170.03193.060.0083--1.4079,951.98-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Peijia Medical Ltd477.41m-424.81m2.49bn1.04k--1.01--5.21-0.6255-0.62550.70283.620.14730.77739.51459,045.10-13.11-34.08-14.94-36.9073.7671.62-88.99-448.756.92--0.0886--75.86--3.75------
Frontage Holdings Corp2.03bn84.45m2.50bn1.76k30.100.93486.921.230.04090.04090.9811.320.46360.635.321,154,294.001.914.462.335.2830.1734.004.139.921.394.090.2960.003.7925.61-58.00-0.782640.43--
Laekna Inc0.00-399.15m2.57bn89.00--2.95-----3.31-3.310.002.23------0.00-------------------5.280.0655------52.81------
MicroPort CardioFlow Medtech Corp363.87m-510.32m2.75bn592.00--1.09--7.56-0.2159-0.21590.1541.050.12052.783.67614,640.80-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-11.560.0293--33.94---3.77---14.16--
Golden Throat Holdings Group Co Ltd1.04bn270.74m2.84bn869.0010.491.699.072.730.36620.36621.412.270.41814.821.851,197,292.0010.8811.0015.8515.6372.5772.7926.0224.672.4834.740.2183.15-3.096.73-11.0419.61-32.1338.94
HighTide Therapeutics Inc0.00-594.96m3.48bn66.00--4.20-----1.26-1.26--1.61------0.00-------------------0.37980.0229-------393.76------
China Isotope & Radiation Corp7.18bn401.48m3.52bn3.11k8.760.69273.240.491.261.2622.4515.880.53124.221.842,312,623.006.216.5712.8213.2652.4859.8911.7012.621.73--0.191928.277.8215.35-5.432.883.632.92
CARsgen Therapeutics Holdings Ltd0.00-809.30m3.55bn516.00--1.82-----1.46-1.460.003.390.00----0.00-29.79---32.14----------9.54--0.0452------16.19------
Data as of May 10 2024. Currency figures normalised to Laekna Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.03%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 04 Apr 202480.50k0.02%
China Asset Management (Hong Kong) Ltd.as of 31 Dec 202336.00k0.01%
Data from 31 Dec 2023 - 09 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.